Hubei Jumpcan Pharmaceutical Co Ltd banner
H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 26.72 CNY 0.15% Market Closed
Market Cap: ¥24.6B

EV/S

2.3
Current
15%
More Expensive
vs 3-y average of 2

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.3
=
Enterprise Value
¥13.6B
/
Revenue
¥5.9B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
2.3
=
Enterprise Value
¥13.6B
/
Revenue
¥5.9B

Valuation Scenarios

Hubei Jumpcan Pharmaceutical Co Ltd is trading above its 3-year average

If EV/S returns to its 3-Year Average (2), the stock would be worth ¥23.2 (13% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-13%
Maximum Upside
+51%
Average Upside
17%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 2.3 ¥26.72
0%
3-Year Average 2 ¥23.2
-13%
5-Year Average 2 ¥23.17
-13%
Industry Average 3.5 ¥40.39
+51%
Country Average 3.3 ¥38.22
+43%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥13.6B
/
Apr 2026
¥5.9B
=
2.3
Current
¥13.6B
/
Dec 2026
¥6.8B
=
2
Forward
¥13.6B
/
Dec 2027
¥7.5B
=
1.8
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
CN
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
24.6B CNY 2.3 14.2
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 13.2 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 6 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.7 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 5.2 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 5.3 19.9
US
Merck & Co Inc
NYSE:MRK
272.3B USD 4.7 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 108.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4.1 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 3.2 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 3.1 16.6

Market Distribution

In line with most companies in China
Percentile
38th
Based on 7 593 companies
38th percentile
2.3
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.

Intrinsic Value
21.7 CNY
Overvaluation 19%
Intrinsic Value
Price ¥26.72
H
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett